The ALDH1B1 Knockout SK-OV-3 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ALDH1B1 gene in the SK-OV-3 human ovarian adenocarcinoma cell line. This polyclonal knockout population offers a pool of genome-edited cells that collectively exhibits loss-of-function of ALDH1B1, enabling robust functional studies without the artifact risks associated with single-cell cloning. The population diversity mimics the genetic heterogeneity of tumors, making it suitable for broad pharmacological and biological assessments.
The SK-OV-3 cell line originates from the ascitic fluid of a Caucasian female with progressive ovarian adenocarcinoma. This TP53-mutant and HER2-positive line is a well-established model for aggressive ovarian cancer, characterized by dysregulated DNA damage responses and enhanced receptor tyrosine kinase signaling. SK-OV-3 cells exhibit adherent epithelial morphology and are tumorigenic in vivo, serving as a platform for investigating mechanisms of chemoresistance, metastasis, and the role of cancer stem cells. The line??s molecular background provides a clinically relevant context for ALDH1B1 knockout studies, particularly in relation to retinoic acid metabolism and tumor-initiating cell populations.
ALDH1B1 encodes a mitochondrial aldehyde dehydrogenase that catalyzes the oxidation of retinaldehyde to retinoic acid, a critical metabolite activating RAR/RXR nuclear receptors. In the SK-OV-3 model, ALDH1B1 is transcriptionally regulated by Wnt/??-catenin and Notch pathways, and it operates in concert with other ALDH family members and retinoid binding proteins. The enzyme directly interacts with aldehyde substrates and is part of a broader retinoic acid metabolic network involving CYP26-mediated catabolism. Downstream of ALDH1B1, retinoic acid promotes the expression of stemness markers NANOG and SOX2 through RAR/RXR response elements, thereby sustaining cancer stem cell self-renewal. CRISPR/Cas9-mediated disruption of ALDH1B1 abolishes its enzymatic activity, leading to an accumulation of aldehydes and a reduction in retinoic acid synthesis. This metabolic shift impairs the activation of retinoic acid-responsive genes and diminishes the maintenance of stem cell?Clike properties, ultimately sensitizing cells to cytotoxic stresses.
In the SK-OV-3 context, high ALDH1B1 activity marks a subpopulation of ovarian cancer stem cells that contribute to tumor propagation and therapy resistance. Loss-of-function through this polyclonal knockout model reduces the Aldefluor-positive fraction, attenuates sphere-forming capacity, and suppresses the expression of downstream stemness factors. The accumulation of aldehydes, including acetaldehyde, further stresses the cells, potentially enhancing the effects of DNA-damaging agents such as cisplatin. Since the knockout is not clonal, the cell population retains a range of editing events, which better reflects the heterogeneous nature of tumor cell populations and allows for the selection of adaptive mechanisms that may arise during drug treatment. This model is therefore highly instructive for dissecting how ALDH1B1-mediated retinoic acid production and aldehyde detoxification govern the balance between differentiation and stemness in ovarian adenocarcinoma.
Researchers can utilize the ALDH1B1 Knockout SK-OV-3 Polyclonal Cells for a wide array of experimental applications, including investigation of ovarian cancer stem cell biology, elucidation of drug resistance mechanisms to platinum and taxane chemotherapeutics, and analysis of alcohol metabolism in malignancy. Typical assays include quantitation of retinoic acid by mass spectrometry, western blotting and RT-qPCR for proteins such as ALDH1B1, NANOG, and SOX2, Aldefluor activity measurement, and sphere formation analysis. Functional studies can assess changes in cell proliferation, migration, and invasion, as well as drug sensitivity profiling using compounds like cisplatin and paclitaxel. These cells are also valuable for in vivo xenograft models to evaluate tumorigenicity and therapeutic response in a defined genetic context. For further details and technical support, please contact Ascent Research.
